Advanced

Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.

Mattiasson, Anders LU ; Abrams, P; Van Kerrebroeck, P; Walter, S and Weiss, J (2002) In BJU International1999-01-01+01:00 89(9). p.855-862
Abstract
OBJECTIVE: To investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in men. PATIENTS AND METHODS: Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited. A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg). After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks. RESULTS: In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo). In the desmopressin group 28 (34%) patients... (More)
OBJECTIVE: To investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in men. PATIENTS AND METHODS: Men aged >/=18 years with verified nocturia (>or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited. A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg). After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks. RESULTS: In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo). In the desmopressin group 28 (34%) patients and in the placebo group two (3%) patients (P<0.001) had fewer than half the number of nocturnal voids relative to baseline; the mean number of nocturnal voids decreased from 3.0 to 1.7 and from 3.2 to 2.7, respectively, reflecting a mean decrease of 43% and 12% (P<0.001). The mean duration of the first sleep period increased by 59% (from 2.7 to 4.5 h) in the desmopressin group, compared with an increase of 21% (from 2.5 to 2.9 h) in the placebo group (P<0.001). The mean nocturnal diuresis decreased by 36% (from 1.5 to 0.9 mL/min) in the desmopressin group and by 6% (from 1.7 to 1.5 mL/min) in the placebo group (P<0.001). The mean ratio of night/24-h urine volume decreased by 23% and 1% (P<0.001), and the mean ratio of night/day urine volume decreased by 27% and increased by 3% (P<0.001) for the desmopressin and placebo groups, respectively. In the double-blind treatment period, similar numbers of patients had adverse events; 15 (17%) patients in the desmopressin and 16 (25%) patients in the placebo group. Most adverse events were mild. Serum sodium levels were <130 mmol/L in 10 (4%) patients and this occurred during dose-titration. CONCLUSIONS: Orally administered desmopressin is an effective and well-tolerated treatment for nocturia in men. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Renal Agents : administration & dosage, Middle Age, Male, Human, Double-Blind Method, Desmopressin : administration & dosage, Comparative Study, 80 and over, Aged, Adult, Administration, Oral, Treatment Outcome, Urination Disorders : drug therapy
in
BJU International1999-01-01+01:00
volume
89
issue
9
pages
855 - 862
publisher
Blackwell Science Ltd
external identifiers
  • wos:000176083300006
  • pmid:12010228
  • scopus:0036098313
ISSN
1464-4096
DOI
10.1046/j.1464-410X.2002.02791.x
language
English
LU publication?
yes
id
00279290-4cea-44f4-8b6c-6c104d15c94f (old id 108210)
alternative location
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=12010228&dopt=Abstract
date added to LUP
2007-07-18 13:07:00
date last changed
2017-12-10 03:49:23
@article{00279290-4cea-44f4-8b6c-6c104d15c94f,
  abstract     = {OBJECTIVE: To investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in men. PATIENTS AND METHODS: Men aged &gt;/=18 years with verified nocturia (&gt;or=two voids/night) and nocturnal urine production greater than their maximum functional bladder capacity were recruited. A 3-week dose-titration phase established the optimum desmopressin dose (0.1, 0.2 or 0.4 mg). After a 1-week 'washout' period, patients who responded in the dose-titration period were randomized to receive the optimal dose of desmopressin or placebo in a double-blind design for 3 weeks. RESULTS: In all, 151 patients entered the double-blind period (86 treated with desmopressin, 65 with placebo). In the desmopressin group 28 (34%) patients and in the placebo group two (3%) patients (P&lt;0.001) had fewer than half the number of nocturnal voids relative to baseline; the mean number of nocturnal voids decreased from 3.0 to 1.7 and from 3.2 to 2.7, respectively, reflecting a mean decrease of 43% and 12% (P&lt;0.001). The mean duration of the first sleep period increased by 59% (from 2.7 to 4.5 h) in the desmopressin group, compared with an increase of 21% (from 2.5 to 2.9 h) in the placebo group (P&lt;0.001). The mean nocturnal diuresis decreased by 36% (from 1.5 to 0.9 mL/min) in the desmopressin group and by 6% (from 1.7 to 1.5 mL/min) in the placebo group (P&lt;0.001). The mean ratio of night/24-h urine volume decreased by 23% and 1% (P&lt;0.001), and the mean ratio of night/day urine volume decreased by 27% and increased by 3% (P&lt;0.001) for the desmopressin and placebo groups, respectively. In the double-blind treatment period, similar numbers of patients had adverse events; 15 (17%) patients in the desmopressin and 16 (25%) patients in the placebo group. Most adverse events were mild. Serum sodium levels were &lt;130 mmol/L in 10 (4%) patients and this occurred during dose-titration. CONCLUSIONS: Orally administered desmopressin is an effective and well-tolerated treatment for nocturia in men.},
  author       = {Mattiasson, Anders and Abrams, P and Van Kerrebroeck, P and Walter, S and Weiss, J},
  issn         = {1464-4096},
  keyword      = {Renal Agents : administration & dosage,Middle Age,Male,Human,Double-Blind Method,Desmopressin : administration & dosage,Comparative Study,80 and over,Aged,Adult,Administration,Oral,Treatment Outcome,Urination Disorders : drug therapy},
  language     = {eng},
  number       = {9},
  pages        = {855--862},
  publisher    = {Blackwell Science Ltd},
  series       = {BJU International1999-01-01+01:00},
  title        = {Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.},
  url          = {http://dx.doi.org/10.1046/j.1464-410X.2002.02791.x},
  volume       = {89},
  year         = {2002},
}